Morphogen-IX

company

About

MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
£1.50M
Industries
Biotechnology,Genetics,Health Care,Medical
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins as a novel therapy for the treatment for pulmonary arterial hypertension

Pulmonary arterial hypertension is a severe and life-limiting disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments mainly target symptoms and the prognosis remains poor. The only effective cure is transplantation of the lungs or heart and lungs, which has associated risks and complications.

Compromised bone morphogenetic protein (BMP) receptor type II (BMPR-II) signalling in endothelial cells plays a pivotal role in the pathobiology PAH, as identified from human genetic studies.

BMP9 and 10 represent circulating ligands that selectively bind and activate BMPR-II receptor complexes on endothelial cells. Administration of exogenous BMP9 has been shown to augment endothelial BMPR-II signalling and reverse PAH in several rodent models of disease.

Our goal is to explore the potential of BMP9 and BMP10 as potential therapies for PAH.

The company follows the semi-virtual model with a hub based in Cambridge, UK. The company founders are experts in the field of PAH and BMPs. The team is staffed with experienced drug discovery professionals to direct an out-sourced development program. This model ensures maximum capital efficiency without sacrificing quality.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
£19.90M
Morphogen-IX has raised a total of £19.90M in funding over 2 rounds. Their latest funding was raised on Dec 18, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 18, 2018 Series B £18.40M 1 Detail
Jan 18, 2016 Series A £1.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Morphogen-IX is funded by 1 investors. Cambridge Innovation Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Cambridge Innovation Capital Series B